Related Experiment Video
Updated: May 26, 2026

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function
Published on: March 15, 2022
Antiplatelet therapy in ENT surgery: a review
D C Sylvester1, A P Coatesworth
1Department of Otolaryngology, York Hospital, UK. dsylvester@doctors.net.uk
Insights
Prematurely stopping antiplatelet agents like aspirin and clopidogrel poses significant risks of morbidity and mortality. Multidisciplinary consultation is crucial for managing these agents during the peri-operative period, especially for ENT surgeries.
Area of Science:
- Otorhinolaryngology
- Cardiology
- Pharmacology
Background:
- Antiplatelet agents (e.g., aspirin, clopidogrel) are common in clinical practice.
- Otorhinolaryngological surgeons face decisions regarding peri-operative antiplatelet therapy.
- Balancing hemorrhage risk (continuation) versus thrombosis risk (cessation) is critical.
Purpose of the Study:
- To review literature on hemorrhage risks with antiplatelet agents.
- To evaluate morbidity and mortality associated with antiplatelet agent cessation.
- To present a management protocol for peri-operative antiplatelet agents in ENT surgery.
Main Methods:
- Literature review on spontaneous and operative hemorrhage risks.
- Evaluation of morbidity and mortality from drug cessation.
- Assessment of existing published guidelines.
- Development of a peri-operative management protocol.
Main Results:
- Significant morbidity and mortality linked to premature antiplatelet agent cessation.
- Marginal increase in operative blood loss in patients on aspirin and clopidogrel (cardiac surgery data).
Conclusions:
- Premature cessation of antiplatelet agents carries substantial risks.
- Multidisciplinary consultation is essential for peri-operative management decisions.
- A protocol for managing antiplatelet agents in ENT surgery is proposed.
Introduction:
Antiplatelet agents such as aspirin and clopidogrel are increasingly encountered in clinical practice. Otorhinolaryngological surgeons are involved in the peri-operative decision of whether to continue treatment and risk haemorrhage or to discontinue treatment and risk thrombosis.
Methods:
Literature relating to the risk of spontaneous or operative haemorrhage was reviewed. The morbidity and mortality associated with cessation of agents was evaluated. Published guidelines were also evaluated. A protocol for the management of antiplatelet agents in the peri-operative period, with particular reference to ENT operations, is presented.
Conclusion:
SIGNIFICANT morbidity and mortality is associated with the premature cessation of antiplatelet agents. Data from cardiac surgery suggest that operative blood loss only marginally increases in patients on aspirin and clopidogrel. However, the management of antiplatelet agents in the peri-operative period should be made after multidisciplinary consultation.
Related Concept Videos
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Venous Thrombosis III: Interprofessional Care
Peripheral Artery Disease III: Interprofessional Care
Aneurysm IV: Nursing Management
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
Peptic Ulcer Disease IV: Management
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current medication...